BNP Paribas Financial Markets’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

BNP Paribas Financial Markets’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-41	Closed	-$22	–	4565
2019 Q4	$22	Sell	41 -1,084	-96%	-$2.63K	﹤0.01%	4378
2019 Q3	$4.29K	Hold	1,125	–	–	﹤0.01%	4290
2019 Q2	$7.48K	Buy	+1,125	New	+$4.28K	﹤0.01%	4169
2019 Q1	–	Sell	-556	Closed	-$2.21K	–	4467
2018 Q4	$2.21K	Buy	556 +426	+328%	+$5.45K	﹤0.01%	3784
2018 Q3	$2.58K	Hold	130	–	–	﹤0.01%	4227
2018 Q2	$4.14K	Sell	130 -460	-78%	-$16.6K	﹤0.01%	4148
2018 Q1	$21.8K	Buy	590 +57	+11%	+$3.75K	﹤0.01%	3906
2017 Q4	$42.1K	Buy	+533	New	+$39.4K	﹤0.01%	3755

BNP Paribas Financial Markets's MLNT Position: Q1 2020 in Review

BNP Paribas Financial Markets sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 41 shares — an estimated $22 sold.

BNP Paribas Financial Markets first reported a position in MLNT in Q4 2017 and held it in 8 quarters. The position peaked at $42.1K in Q4 2017. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

BNP Paribas Financial Markets reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
BNP Paribas Financial Markets sold 41 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $22.
BNP Paribas Financial Markets first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 8 quarters.
BNP Paribas Financial Markets's Melinta Therapeutics, Inc. Common Stock position peaked at $42.1K in Q4 2017.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2020, filed 13 May 2020.